By Rob Curran


Shares of Inhibikaise Therapeutics rose in premarket trading Wednesday after the company said the Food and Drug Administration gave permission for it to resume a trial of IkT-148009, its Parkinson's disease drug candidate.

The Atlanta-based biotechnology company expects to reopen clinical-trial sites and start enrolling patients in the mid-stage trial for IkT-148009 by the end of the first quarter.

The FDA had requested certain changes to the monitoring of eye conditions and the gauging of the safety of a 200-milligram dose of the drug candidate in healthy patients.

"We believe that we now have clarity on the FDA's expectations as we move forward in the 201 clinical trial for IkT-148009," said President and Chief Executive Milton Werner.

In early December, Inhibikaise disclosed the FDA's request to halt the clinical trial.

Shares were 20.9% higher at $1.10 in premarket trading.


Write to Rob Curran at rob.curran@wsj.com


(END) Dow Jones Newswires

01-25-23 0938ET